ReviewJAMA2013
Management of active Crohn disease.
Review in JAMA, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03291743 (The Biologic Onset of Crohn's Disease), which is not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.Inflammatory bowel diseases · 2026Pooled it
- Exploring the Potential Link Between Autoimmune Diseases and Pan-Cancer: A Multidatabase Mendelian Randomization Analysis.Journal of immunology research · 2025Pooled it
- The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.Digestive diseases and sciences · 2015Pooled it
- Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Fatigue in Inflammatory Bowel Disease: The Role of Drug Therapy Within a Holistic Management Framework.Drugs · 2026Review
- Rethinking risk in Crohn's surgery: age at onset fails to predict surgical outcomes after ileocecal resection, insights from a tertiary referral center.Techniques in coloproctology · 2026Article
- The Knowledge, Attitude, and Perception (KAP) of Healthcare Professionals in Pediatric Settings Toward Oral Manifestations of Inflammatory Bowel Disease (IBD): A Survey-Based Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Lack of disparities in postoperative care after ileocecal resection in patients with Crohn's disease at tertiary inflammatory bowel diseases centers.Therapeutic advances in gastroenterology · 2026Article
- Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease.Scientific reports · 2025Article
- Real-World Treatment Patterns Among Pediatric and Adult Patients with Crohn's Disease in the United States.Drugs - real world outcomes · 2025Article
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Enterocutaneous Fistula in a Patient with Crohn's Disease After Internalization of a Foreign Body into the Gastrointestinal Tract.Journal of clinical medicine · 2025Article
- Typing of feces-derived Candida albicans strains using a novel seven-locus microsatellite panel reveals associations with yeast phenotype in individuals with inflammatory bowel disease.Pathogens and disease · 2025Article
- Network modeling of the impact of social support and illness acceptance on disease activity in Crohn's disease patients: a cross-sectional study.Frontiers in psychology · 2025Article
- Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.Gastro hep advances · 2025Review
- Type 2 Diabetes Mellitus in Inflammatory Bowel Disease Patients: A Case-Control Study Through a Long Follow-Up Period.Journal of clinical medicine · 2024Article
- Association between hepcidin levels and inflammatory bowel disease: A systematic review and meta-analysis of observational studies.Food science & nutrition · 2024Review
- Review
- Persistent dysbiosis of duodenal microbiota in patients with controlled pediatric Crohn's disease after resolution of inflammation.Scientific reports · 2024Article
- Ileal inflammation is reduced due to treatment with a metalloprotease from BmooMP-α-I snake venom in an experimental model of Toxoplasma gondii infection.Parasitology research · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
importanceTreatment of Crohn disease is rapidly evolving, with the induction of novel biologic therapies and newer, often more intensive treatment approaches. Knowing how to treat individual patients in this quickly changing milieu can be a challenge.
objectiveTo review the diagnosis and management of moderate to severe Crohn disease, with a focus on newer treatments and goals of care. EVIDENCE REVIEW: MEDLINE was searched from 2000 to 2011. Additional citations were procured from references of select research and review articles. Evidence was graded using the American Heart Association level-of-evidence guidelines.
resultsAlthough mesalamines are still often used to treat Crohn disease, the evidence for their efficacy is lacking. Corticosteroids can be effectively used to induce remission in moderate to severe Crohn disease, but they do not maintain remission. The mainstays of treatment are immunomodulators and biologics, particularly anti-tumor necrosis factor. CONCLUSION AND RELEVANCE: Immunomodulators and biologics are now the preferred treatment options for Crohn disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.